4.3 Review

Overcoming Therapeutic Inertia as the Achilles' Heel for Improving Suboptimal Diabetes Care: An Integrative Review

Journal

ENDOCRINOLOGY AND METABOLISM
Volume 38, Issue 1, Pages 34-42

Publisher

KOREAN ENDOCRINE SOC
DOI: 10.3803/EnM.2022.1649

Keywords

Diabetes mellitus; Therapeutics; Medication adherence

Ask authors/readers for more resources

The ultimate goal of diabetes care is to achieve outcomes that are important to patients throughout their lives. However, the levels of treatment target achievement in people with diabetes mellitus have not been optimal despite advancements in various aspects of healthcare. Clinical inertia, particularly therapeutic inertia, is a key underlying problem that hinders effective treatment modifications when treatment goals are not met.
The ultimate purpose of diabetes care is achieving the outcomes that patients regard as important throughout the life course. Despite advances in pharmaceuticals, nutraceuticals, psychoeducational programs, information technologies, and digital health, the levels of treatment target achievement in people with diabetes mellitus (DM) have remained suboptimal. This clinical care of people with DM is highly challenging, complex, costly, and confounded for patients, physicians, and healthcare systems. One key underlying prob-lem is clinical inertia in general and therapeutic inertia (TI) in particular. TI refers to healthcare providers' failure to modify therapy appropriately when treatment goals are not met. TI therefore relates to the prescribing decisions made by healthcare professionals, such as doctors, nurses, and pharmacists. The known causes of TI include factors at the level of the physician (50%), patient (30%), and health system (20%). Although TI is often multifactorial, the literature suggests that 28% of strategies are targeted at multiple levels of causes, 38% at the patient level, 26% at the healthcare professional level, and only 8% at the healthcare system level. The most effective interventions against TI are shorter intervals until revisit appointments and empowering nurses, diabetes educators, and pharmacists to review treatments and modify prescriptions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available